Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment

Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment

Systemic sclerosis is an immune-mediated disease characterized by a chronic progressive course. The complex and diverse clinical features seen in patients require case-by-case approach and cooperation of multiple specialists both at the stage of diagnosis and treatment. Critical factors in systemic...

Full description

Bibliographic Details
Main Authors:	Dorota Krasowska, Lidia Rudnicka, Aleksandra Dańczak-Pazdrowska, Grażyna Chodorowska, Anna Woźniacka, Anna Lis-Święty, Joanna Czuwara, Joanna Maj, Sławomir Majewski, Anna Sysa-Jędrzejowska, Anna Wojas-Pelc
Format:	Article
Language:	English
Published:	Termedia Publishing House 2017-12-01
Series:	Przegląd Dermatologiczny
Subjects:	methotrexate alprostadil sildenafil mycophenolate mofetil cyclophosphamide scleroderma guidelines
Online Access:	https://www.termedia.pl/Systemic-sclerosis-diagnostic-and-therapeutic-recommendations-of-the-Polish-Dermatological-Society-Part-2-treatment,56,31170,1,1.html

Similar Items

Localized scleroderma (morphea). Diagnostic and therapeutic recommendations of the Polish Dermatological Society
by: Dorota Krasowska, et al.
Published: (2019-10-01)

Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring
by: Dorota Krasowska, et al.
Published: (2017-11-01)

Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study
by: Kristofer Andréasson, et al.
Published: (2020-10-01)

Long-Term Outcome of Patients with Lupus Nephritis: A Single Center Experience
by: Senija Rašić, et al.
Published: (2010-04-01)

Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis – A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria
by: Kristina Vollbach, et al.
Published: (2022-04-01)

Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
by: Arun Sedhain, et al.
Published: (2018-07-01)

Current and emerging treatment options in the management of lupus
by: Jordan N, et al.
Published: (2016-03-01)

Dermatomyositis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society
by: Adam Reich, et al.
Published: (2021-06-01)

Real-World Effectiveness of Belimumab in Patients with Active Lupus
by: Yuya Sumichika, et al.
Published: (2023-12-01)

Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy
by: Lei Peng, et al.
Published: (2016-01-01)

STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
by: O A Koneva, et al.
Published: (2011-08-01)

A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
by: Annemarie Schorpion, et al.
Published: (2018-05-01)

Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: A retrospective cohort study
by: Qing Jia, et al.
Published: (2022-08-01)

Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2023-03-01)

Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study
by: Shefali Khanna Sharma, et al.
Published: (2020-08-01)

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
by: Anji Xiong, et al.
Published: (2021-03-01)

Recent advances in the treatment of systemic sclerosis associated interstitial lung disease
by: Antoniya Kamenova, et al.
Published: (2023-03-01)

Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study
by: Xiaohui Zhang, et al.
Published: (2023-07-01)

Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies
by: Corrado Campochiaro, et al.
Published: (2024-04-01)

Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma [version 1; peer review: 2 approved]
by: Thomas Jaki, et al.
Published: (2021-09-01)

Mediastinal tuberculous abscess: A rare presentation after renal transplant
by: Sukanto K Das, et al.
Published: (2019-01-01)

Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?: A mini-review
by: Alice Tung Wan Song, et al.

Mycophenolate mofetil as second line immunosuppressant in myasthenia gravis - a long-term prospective open-label study
by: Hanisch F, et al.
Published: (2009-08-01)

Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases
by: Qian Li, et al.
Published: (2022-12-01)

Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study
by: Xuan Luo, et al.
Published: (2020-07-01)

Short story of antirheumatic therapy.VIII. The immunodepressants
by: P. Marson, et al.
Published: (2012-03-01)

Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide
by: Xuebing Zhang, et al.
Published: (2020-11-01)

Comparison of mid-term clinical outcome in heart transplantation patients using mycophenolate mofetil vs. enteric-coated mycophenolate sodium
by: Kina Jeon, et al.
Published: (2022-08-01)

Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis
by: David Dias-Polak, et al.
Published: (2019-01-01)

Duodenal villous atrophy caused by Mycophenolate Mofetil in patients with solid organ transplantation: case report
by: Giuston Mendoza-Chuctaya, et al.
Published: (2016-03-01)

Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
by: Seung Woon Park, et al.
Published: (2016-06-01)

Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review
by: Domenico Paolo Emanuele Margiotta, et al.
Published: (2018-03-01)

Autoimmune Ascites Responding to Mycophenolate Mofetil: A Case Report
by: Douglas A. Simonetto, et al.
Published: (2018-05-01)

Mycophenolate Mofetil and Clostridium difficile-associated Colitis
by: A. I. Dolgushina, et al.
Published: (2021-12-01)

Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis
by: George N. Dalekos, et al.
Published: (2022-12-01)

Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
by: Wang Pengfei, et al.
Published: (2023-11-01)

Simultaneous Spectrophotometric Determination of Mycophenolate Mofetil and Its Active Metabolite in Human Plasma Using Chemometrics Methods
by: Tayyebeh Madrakian, et al.
Published: (2015-06-01)

Severe Complications from an Unexpectedly High Serum Mycophenolic Acid Concentration in a Patient with Renal Failure Secondary to Lupus Nephritis: A Case Report
by: Yuji Doi, et al.
Published: (2019-06-01)

Mycophenolate mofetil-related colitis in a paediatric patient after kidney transplant
by: Natalia Oleksik, et al.
Published: (2022-10-01)

Mycophenolate mofetil in the treatment of non-renal manifestations of systemic lupus erythematosus: recent insights
by: Ali SAHIN
Published: (2010-05-01)